Cell Death Dis

PubMed DOI Crossref

Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status.

Das I, Wilhelm M, Höiom V, ..., Tuominen R, Egyhàzi Brage S

pii pmc

Cell Death Dis 10 (9) 663 [2019-09-10; online 2019-09-10]

NGI Uppsala (Uppsala Genome Center) [Service]

PubMed DOI Crossref

Metabolic reprogramming of acute lymphoblastic leukemia cells in response to glucocorticoid treatment

Dyczynski M, Vesterlund M, Björklund AC, ..., Tamm KP, Nilsson R

Cell Death Dis 9 (9) - [2018-09-00; online 2018-08-28]

Chemical Proteomics & Proteogenomics [Collaborative]

PubMed DOI Crossref

A patient-derived xenograft pre-clinical trial reveals treatment responses and a resistance mechanism to karonudib in metastatic melanoma.

Einarsdottir BO, Karlsson J, Söderberg EMV, ..., Helleday T, Nilsson JA

pii pmc

Cell Death Dis 9 (8) 810 [2018-07-24; online 2018-07-24]

Bioinformatics Compute and Storage [Service] NGI Stockholm (Genomics Applications) [Service] NGI Stockholm (Genomics Production) [Service]

PubMed DOI Crossref

Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells.

Azimi A, Tuominen R, Costa Svedman F, ..., Hansson J, Egyhazi Brage S

pii pmc ProteomXchange

Cell Death Dis 8 (8) e3029 [2017-08-31; online 2017-08-31]

Chemical Proteomics & Proteogenomics [Service] Clinical Proteomics Mass spectrometry [Service] NGI Stockholm (Genomics Applications) [Service] NGI Stockholm (Genomics Production) [Service] NGI Uppsala (Uppsala Genome Center) [Service]